Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 - Goldman, Jason D; Lye, David C.B; Hui, David S; Marks, Kristen M; Bruno, Raffaele; Montejano, Rocio; Spinner, Christoph D; Galli, Massimo; Ahn, Mi-Young; Nahass, Ronald G; Chen, Yao-Shen; SenGupta, Devi; et al. (The New England journal of medicine, 2020)
Keywords: Adenosine Monophosphate - administration & dosage; Adenosine Monophosphate - adverse effects; Adenosine Monophosphate - analogs & derivatives; Adult; Aged; Alanine; Alanine - administration & dosage; Alanine - adverse effects; Alanine - analogs & derivatives; Alanine transaminase; Animal models; Antiviral activity; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral drugs; Betacoronavirus; Confidence intervals; Constipation; Coronavirus Infections - drug therapy; Coronavirus Infections - mortality; Coronavirus Infections - therapy; Coronaviruses; COVID-19; Creatinine; Disease; DNA-directed RNA polymerase; Drug Administration Schedule; Female; Hospitalization; Humans; Intravenous administration; Male; Mechanical ventilation; Middle Aged; Nausea; Original; Oxygen Inhalation Therapy; Pandemics; Patients; Pneumonia, Viral - drug therapy; Pneumonia, Viral - mortality; Pneumonia, Viral - therapy; Respiratory failure; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Treatment Outcome; United States--US